Pediatric healthcare provider Pediatrix Medical Group (NYSE: MD) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 4% year on year to $487.8 million. Its non-GAAP profit of $0.63 per share was 6.6% above analysts’ consensus estimates.

Is now the time to buy Pediatrix Medical Group? Find out by accessing our full research report, it’s free.

“Our strong results this quarter were in line with our expectations and reflect continued favorable trends in the performance of recent acquisitions and same-unit reimbursement metrics,” said Mark S. Ordan, Chief Executive Officer of Pediatrix Medical Group.

Company Overview

With a network of approximately 2,620 affiliated physicians caring for some of the most vulnerable patients, Pediatrix Medical Group (NYSE: MD) provides specialized physician services focused on neonatal, maternal-fetal, pediatric cardiology and other pediatric subspecialty care across 37 states.

Revenue Growth

A company’s long-term performance is an indicator of its overall quality. Any business can have short-term success, but a top-tier one grows for years. Over the last five years, Pediatrix Medical Group grew its sales at a tepid 1.7% compounded annual growth rate. This was below our standards and is a tough starting point for our analysis.

We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. Pediatrix Medical Group’s performance shows it grew in the past but relinquished its gains over the last two years, as its revenue fell by 1.3% annually.

We can dig further into the company’s revenue dynamics by analyzing its same-store sales, which show how much revenue its established locations generate. Over the last two years, Pediatrix Medical Group’s same-store sales averaged 5.4% year-on-year growth. Because this number is better than its revenue growth, we can see its sales from existing locations are performing better than its sales from new locations.

This quarter, Pediatrix Medical Group reported modest year-on-year revenue growth of 4% but beat Wall Street’s estimates by 2.1%.

Looking ahead, sell-side analysts expect revenue to remain flat over the next 12 months. While this projection suggests its newer products and services will catalyze better top-line performance, it is still below average for the sector.

WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.

This is what the early days of Palantir looked like before it became a giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.

Adjusted Operating Margin

Pediatrix Medical Group’s adjusted operating margin has been trending up over the last 12 months and averaged 10.5% over the last five years. Its profitability was higher than the broader healthcare sector, showing it did a decent job managing its expenses.

Looking at the trend in its profitability, Pediatrix Medical Group’s adjusted operating margin of 12.3% for the trailing 12 months may be around the same as five years ago, but it has increased by 4.4 percentage points over the last two years.

In Q2, Pediatrix Medical Group generated an adjusted operating margin profit margin of 12.4%, down 1.4 percentage points year on year. This reduction is quite minuscule and indicates the company’s overall cost structure has been relatively stable.

Earnings Per Share

Revenue trends explain a company’s historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth — for example, a company could inflate its sales through excessive spending on advertising and promotions.

Pediatrix Medical Group’s EPS grew at 12% compounded annual growth rate over the last five years, higher than its 1.7% annualized revenue growth. However, this alone doesn’t tell us much about its business quality because its adjusted operating margin didn’t improve.

Diving into the nuances of Pediatrix Medical Group’s earnings can give us a better understanding of its performance. A five-year view shows that Pediatrix Medical Group has repurchased its stock, shrinking its share count by 5.3%. This tells us its EPS outperformed its revenue not because of increased operational efficiency but financial engineering, as buybacks boost per share earnings.

In Q2, Pediatrix Medical Group reported adjusted EPS of $0.63, up from $0.53 in the same quarter last year. This print beat analysts’ estimates by 6.6%. Over the next 12 months, Wall Street expects Pediatrix Medical Group’s full-year EPS to stay about the same, moving from $2.24 to $2.26.

Key Takeaways from Pediatrix Medical Group’s Q2 Results

It was encouraging to see Pediatrix Medical Group beat analysts’ revenue expectations this quarter. We were also glad its EPS outperformed Wall Street’s estimates. Overall, this print had some key positives. Investors were likely hoping for more, and shares traded down 12.3% to $23.02 immediately following the results.

Is Pediatrix Medical Group an attractive investment opportunity at the current price? The latest quarter does matter, but not nearly as much as longer-term fundamentals and valuation, when deciding if the stock is a buy. We cover that in our actionable full research report which you can read here (it’s free).